{"nctId":"NCT00558259","briefTitle":"Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE","startDateStruct":{"date":"2007-11"},"conditions":["Venous Thromboembolism"],"count":1353,"armGroups":[{"label":"dabigatran etexilate 150 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: dabigatran etexilate 150 mg twice daily (BID)"]},{"label":"matching placebo twice daily (BID)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: matching placebo twice daily (BID)"]}],"interventions":[{"name":"dabigatran etexilate 150 mg twice daily (BID)","otherNames":[]},{"name":"matching placebo twice daily (BID)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Patients with confirmed symptomatic PE or proximal DVT of the leg(s) who have been treated for 6 to 18 months with therapeutic dosages (intended INR between 2-3) of an oral VKA (e.g. warfarin, acenocoumarol, phenprocoumon, or fluindione) or RE-COVER study medication up to the moment of screening for the current study.\n2. Written informed consent\n\nExclusion criteria:\n\n1. Younger then 18 years of age\n2. Indication for VKA other than DVT and/or PE\n3. Patients in whom anticoagulant treatment for their index PE or DVT should be continued\n4. Active liver disease or liver disease decreasing survival (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or ALAT \\> 3 x ULN\n5. Creatinine clearance \\< 30 ml/min\n6. Acute bacterial endocarditis\n7. Active bleeding or high risk for bleeding.\n8. Uncontrolled hypertension (investigators judgement)\n9. Intake of another experimental drug within the 30 days prior to randomization into the study\n10. Life expectancy \\<6 months\n11. Childbearing potential without proper contraceptive measures\\*, pregnancy or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period","description":"Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"0.0"},{"groupId":"OG001","value":"37","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Excluding Unexplained Death During the Intended Treatment Period","description":"Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period","description":"Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period","description":"Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Centrally Confirmed Unexplained Deaths During the Intended Treatment Period","description":"Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Centrally Confirmed Bleeding Event During the Treatment Period","description":"Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:\n\n* Fatal bleeding\n* Associated with a fall in haemoglobin of ≥2 g/dL\n* Led to the transfusion of ≥2 units packed cells or whole blood\n* Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal\n\nOther clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.\n\nExamples of these bleedings were:\n\n* Bleeding that compromised haemodynamics\n* Bleeding that led to hospitalisation\n\nTrivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.\n\nAll bleeding events include MBEs, CRBEs, and trivial bleeding events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Centrally Confirmed Cardiovascular Events During the Treatment Period","description":"Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Laboratory Measures, Especially Liver Function Tests (LFTs)","description":"Number of participants with possible clinically significant abnormalities during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":684},"commonTop":[]}}}